Phase I trial of an Alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Gregson, Aric L ^a,d   Oliveira, Giane ^a,e   Othoro, Caroline ^b   Calvo Calle, J Mauricio ^b,f   Thorton, George B ^c   Nardin, Elizabeth ^b   Edelman, Robert ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Apovia Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMINO ACID; CIRCUMSPOROZOITE PROTEIN; EPITOPE; HEPATITIS B CORE ANTIGEN; ICC 1132; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; PRECIPITIN; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASSAY; CHILL; CLINICAL TRIAL; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALAISE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PLASMODIUM FALCIPARUM; SPOROZOITE; VIRUS LIKE AGENT; VOLUNTEER; VOMITING; ADOLESCENT; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; MIDDLE AGED; T LYMPHOCYTE; TREATMENT OUTCOME; VIRION;

HEPATITIS B VIRUS; PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; CELL PROLIFERATION; EPITOPES; HEPATITIS B CORE ANTIGENS; HUMANS; MALARIA VACCINES; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRION;

EID: 45249093689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001556     Document Type: Article

References (57)

1. Breman J (2001) The ears of the hippopotamus: Manifestations, determinants, and estimates ofthe malaria burden. Am J Trop Med Hyg 64(1-2 Suppl): 1-11.
2. Clyde D, V M, Miller R, Hornick R (1973) Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266(6): 398-403.
3. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, et al. (1982) Circumsporozoite proteins of human malaria parasites plasmodium falciparum and plasmodium vivax. J Exp Med 156(1): 20-30.
4. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, et al. (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine agains plasmodium falciparum sporozoites. Nature 328(6127): 257-9.
5. Nardin E, Herrington D, Davis J, Levine M, Stuber D, et al. (1989) Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 246(1937): 1603-6.
6. Nardin E, Nussenzweig R (1993) T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 11: 687-727.
7. Sun P, Schwenk R, White Y, Stoute J, Cohen J, et al. (2003) Protective immunity induced with malaria vaccine, RTS,S, is linked to plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171(12): 6961-7.
8. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347(21): 1645-1651.
9. Galarza JM, Latham T, Cupo A (2005) Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18(2): 365-372.
10. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, et al. (2005) Comparison of two cancer vaccines targeting tyrosinase: Plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 11(22): 8114-8121.
11. Huang Y, Liang W, Wang Y, Zhou Z, Pan A, et al. (2005) Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco. Viral Immunol 18(4): 668-677.
12. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, et al. (2005) Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174(1): 449-455.
13. Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, et al. (2006) DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24(14): 2643-2655.
14. Boiang K, Milligan P, Pinder M, Vigneron L, Alloueche A, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against plasmodium falciparum infection in semi-immune adult men in the gambia: A randomised trial. Lancet 358(9297): 1927-34.
15. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental plasmodium falciparum malaria. J Infect Dis 183(4): 640-7.
16. Alonso P, Sacarlal J, Aponte J, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against plasmodium falciparum infection and disease in young african children: Randomised controlled trial. Lancet 364: 1141-20.
17. Alonso PL, Sacarlal J, Aponte J, Leach A, Macete E, et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of plasmodium falciparum disease in mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502): 2012-2018.
18. Stoute J, Slaoui M, Heppner D, Momin P, Kester K, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falcipanum malaria. RTS,S malaria vaccine evaluation group. N Engl J Med 336(2): 86-91.
19. Schodel F, Wirtz R, Peterson D, Hughes J, Warren R, et al. (1994) Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 180(3): 1037-1046.
20. Schodel F, Peterson D, Milich DR, Charoenvit Y, Sadoff J, et al. (1997) Immunization with hybrid hepatitis B virus core particles carrying circurnsporozoite antigen epitopcs protects mice against plasmodium yoelii challenge. Behring Inst Mitt (98)(98): 114-119.
21. Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V (1983) Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med 157(6): 1947-1957.
22. Molano A, Park SH, Chiu YH, Nosseir S, Bendelac A, et al. (2000) Cutting edge: The IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: Exploring the role of GPIs in NK T cell activation and antimalarial responses. J Immunol 164(10): 5005-5009.
23. Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Matile H, et al. (1988) A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336(6201): 778-780.
24. Calvo-Calle J, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro Z, et al. (1997) Binding of malaria T cell epitopies to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T cell epitope in the plasmodium falciparum circumsporozoite protein. J Immunol 159(3): 1362-73.
25. Doolan DL, Hoffman SL, Southwood S, Wentworth PA, Sidney J, et al. (1997) Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7(1): 97-9112.
26. Moreno A, Clavjo P, Edelman R, Davis J, Sztein M, et al. (1993) CD4+ T cell clones obtained from plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 151(1): 489-99.
27. Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, et al. (2000) Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 182(5): 1486-96.
28. Blum-Tirouvanziam U, Servis C, Habluetzel A, Valmori D, Men Y, et al. (1995) Localization of HLA-A2.1-restricted T cell epitopes in die circumsporozoite protein of plasmodium falciparum. J Immunol 154(8): 3922-3931.
29. Birkett A, Lyons I, Schmidt A, Boyd D, Oliveira GA, et al. (2002) A modified hepatitis B virus core particle containing multiple epitopes of the plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 70(12): 6860-70.
30. Nardin E, Oliveira G, Calvo-Calle J, Wetzel K, Maier C, et al. (2004) Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing plasmodium falciparum circumsporozoite epitopes. Infect Immun 72(11): 6519-27.
31. Walther M, Dunachie S, Keating S, Vuola J, Berthoud T, et al. (2005) Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in seppic ISA 720. Vaccine 23(7): 857-64.
32. Oliveira GA, Wetzel K, Calvo-Calte JM, Nussenzweig R, Schmidt A, et al. (2005) Safety and enhanced immunogenicity of a hepatitis B core particle plasmodium falcipartim malaria vaccine formulated in adjuvant montanide ISA 720 in a phase I trial. Infect Immun 73(6): 3587-3597.
33. Boucher B, Wynne S, Crowther R (1997) Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 386(6620): 88-91.
34. Zlotnick A, Cheng N, Stahl S, Conway J, Steven A, et al. (1997) Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: Implications for morphogenesis and organization of encapsidated RNA. Proc Natl Acad Sci U S A 94(18): 9556-61.
35. Vanderberg J, Nussenzweig R, Most H (1969) Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. V. in vitro effects of immune serum on sporozoites. Mil Med 134(10): 1183-1190.
36. Persson C, Oliveira G, Sultan A, Blianot P, V N, et al. (2002) Cutting edge: A new tool to evaluate human pre-erythrocytic malaria vaccines: Rodent parasites bearing a hybrid plasmodium falciparum circumsporozoite protein. J Immunol 169(12): 6681-5.
37. Kumar KA, Oliveira GA, Edelman R, Nardin E, Nussenzweig V (2004) Quantitative plasmodium sporozoite neutralization assay (TSNA). J Immunol Methods 292(1-2): 157-164.
38. Nardin E, Calvo-Calle J, Oliveira G, Nussenzweig R, Schneider M, et al. (2001) A totally synthetic polyoxime malaria vaccine containing plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 166(1): 481-9.
39. R Development Core Team (2007) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
40. Yin JZ, Bell MK, Thorbecke GJ (1989) Effect of various adjuvants on the antibody response of mice to pneumococcal polysaccharides. J Biol Response Mod 8(2): 190-205.
41. Wong VK, Quagliata R, Adler R, Kim KS (1991) Dose-related immunogenicity of haemophilus influenzae type b capsular polysaccharide-neisseria meningitidis outer membrane protein conjugate vaccine. Am J Dis Child 145(7): 742-745.
42. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr, Nichols R, et al. (2001) Safety and immunogenicity of increasing doses of a clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69(2): 988-995.
43. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, et al. (1987) Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330(6149): 664-6.
44. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, et al. (2005) Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 73(5): 2863-2872.
45. Bomford R (1984) Relative adjuvant efficacy of al(OH)3 and saponin is related to the immunogenicity of the antigen. Int Arch Allergy Appl Immunol 75(3): 280-281.
46. Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, et al. (1986) Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232(4752): 881-884.
47. Maheshwari RK, Czarniecki CW, Dutta GP, Puri SY, Dhawan BN, et al. (1986) Recombinant human gamma interferon inhibits simian malaria. Infect Immun 53(3): 628-630.
48. de Koning-Ward TF, O'Donnell RA, Drew DR, Thomson R, Speed TP, et al. (2003) A new rodent model to assess blood stage immunity to the plasmodium falcipartim antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 198(6): 869-875.
49. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, et al. (2004) Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage plasmodium falciparum infection in individuals in a endemic area of africa. J Immunol 113(1): 666-672.
50. Edelman R, Hoffman S, Davis J, Beier M, Sztein M, et al. (1993) Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated plasmodium falciparum sporozoites. J Infect Dis 168(4): 1066-70.
51. Gordon D, McGovern T, Krzych U, Cohen J, Schneider I, et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171(6): 1576-85.
52. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS (1984) Inhibition of entry of plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. Journal of Immunology 132(2): 909-13.
53. Hoffman S, Wistar RJ, Ballou W, Hollingdale M, Wirtz R, et al. (1986) Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of plasmodium falciparum. N Engl J Med 315(10): 601-6.
54. Wirtz RA, Ballou WR, Schneider I, Chedid L, Gross MJ, et al. (1987) Plasmodium flalciparum: Immunogenicity of circumsporozoite protein constructs produced in escherichia coli. Exp Parasitol 63(2): 166-172.
55. Hollingdale MR, Hogh B, Petersen E, Wirtz RA, Bjorkmann A (1989) Age-dependent occurrence of protective anti-plasmodium falciparum sporozoite antibodies in a holoendemic area of liberia. Trans R Soc Trop Med Hyg 83(3): 322-324.
56. Hollingdale MR, Appiah A, Leland P, do Rosario VE, Mazier D, et al. (1990) Activity of human volunteer sera to candidate plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes. Trans R Soc Trop Med Hyg 84(3): 325-329.
57. Schwenk R, Asher L, Chalom I, Lanar D, Sun P, et al. (2003) Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol 25(1): 17-25.